These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34823523)

  • 1. Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China.
    Dong Y; Huang H; Deng Y; Xu Y; Chen M; Liu Y; Zhang C
    Malar J; 2021 Nov; 20(1):448. PubMed ID: 34823523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.
    Huang H; Dong Y; Xu Y; Deng Y; Zhang C; Liu S; Chen M; Liu Y
    Malar J; 2021 Mar; 20(1):160. PubMed ID: 33743705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of molecular markers associated with chloroquine resistance in Plasmodium vivax strains from vivax malaria cases in Yunnan Province, China.
    Ding H; Dong Y; Deng Y; Xu Y; Liu Y; Wu J; Chen M; Zhang C; Zheng W
    Malar J; 2023 Jun; 22(1):181. PubMed ID: 37303047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular surveillance of chloroquine resistance in Plasmodium vivax isolates from malaria cases in Yunnan Province of China using pvcrt-o gene polymorphisms.
    Ding H; Dong Y; Deng Y; Xu Y; Liu Y; Wu J; Chen M; Zhang C; Liu L; Lin Y
    Malar J; 2023 Nov; 22(1):338. PubMed ID: 37940956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
    BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
    Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
    Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
    Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study.
    Puaprasert K; Chu C; Saralamba N; Day NPJ; Nosten F; White NJ; Dondorp AM; Imwong M
    Malar J; 2018 Nov; 17(1):427. PubMed ID: 30442143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
    Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; Alves de Brito CF; Gil JP; Nobrega de Sousa T
    J Antimicrob Chemother; 2024 Aug; 79(8):1985-1989. PubMed ID: 38870082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular identification of vivax malaria relapse patients in the Yunnan Province based on homology analysis of the Plasmodium vivax circumsporozoite protein gene.
    Xu Y; Dong Y; Deng Y; Huang H; Chen M; Liu Y; Wu J; Zhang C; Zheng W
    Parasitol Res; 2023 Jan; 122(1):85-96. PubMed ID: 36334150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
    Silvino AC; Costa GL; Araújo FC; Ascher DB; Pires DE; Fontes CJ; Carvalho LH; Brito CF; Sousa TN
    PLoS One; 2016; 11(7):e0160172. PubMed ID: 27467145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of molecular markers associated with drug resistance of Plasmodium vivax isolates in Western Yunnan Province, China.
    Wang X; Ruan W; Zhou S; Feng X; Yan H; Huang F
    BMC Infect Dis; 2020 Apr; 20(1):307. PubMed ID: 32334523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorphism analysis of the block 5 region in merozoite surface protein-1 gene of imported and local Plasmodium vivax in Yunnan Province].
    Dong Y; Sun AM; Chen MN; Xu YC; Mao XH; Deng Y
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2017 Feb; 35(1):1-7. PubMed ID: 30133220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
    Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular surveillance of pvdhfr, pvdhps, and pvmdr-1 mutations in Plasmodium vivax isolates from Yunnan and Anhui provinces of China.
    Huang B; Huang S; Su XZ; Tong X; Yan J; Li H; Lu F
    Malar J; 2014 Sep; 13():346. PubMed ID: 25179752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
    Spring MD; Lon C; Sok S; Sea D; Wojnarski M; Chann S; Kuntawunginn W; Kheang Heng T; Nou S; Arsanok M; Sriwichai S; Vanachayangkul P; Lin JT; Manning JE; Jongsakul K; Pichyangkul S; Satharath P; Smith PL; Dysoley L; Saunders DL; Waters NC
    Am J Trop Med Hyg; 2020 Aug; 103(2):756-759. PubMed ID: 32394887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.